References
- Fenaux P, Mufti GJ, Hellstrom-lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
- Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk Myelodysplastic Syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Rese. J Clin Oncol. 2011;29:1987–1996.
- Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023–2036.
- DeZern AE, Zeidan AM, Barnard J, et al. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*. Leuk Lymphoma. 2017;58:1325–1331
- Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28:241–247.
- Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25:1147–1152.
- Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124:2705 LP–2712.
- Diesch J, Zwick A, Garz A-K, et al. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenet. 2016;8:71.
- Wu P, Geng S, Weng J, et al. The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome. Leuk Res. 2015;39:216–220.
- Qin T, Castoro R, Ahdab S. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. Plos One. 2016;6:e23372. doi: 10.1371/journal.pone.0023372
- Sripayap P, Nagai T, Uesawa M, et al. Mechanisms of resistance to azacitidine in human leukemia cell lines. Exp Hematol. 2014;42:294–306.e2.
- Valencia A, Masala E, Rossi A, et al. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia. 2014;28:621–628.
- Requena CE, Pérez-Moreno G, Horváth A, et al. The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine. Biochem J. 2016;473:2635 LP–2643.
- Hubeek I, Stam RW, Peters GJ, et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer. 2005;93:1388–1394.
- Ciccolini J, Peters GJ, Giovannetti E. Gender, cytidine deaminase, and 5-aza/decitabine-letter. Clin Cancer Res. 2013;19:3105.
- Mahfouz RZ, Jankowska A, Ebrahem Q, et al. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-Azacytidine or decitabine therapy. Clin Cancer Res. 2013;19:938 LP–948.
- Tibaldi C, Giovannetti E, Tiseo M, et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol. 2012;23:670–677.
- Hyo Kim L, Sub Cheong H, Koh Y, et al. Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML. J Hum Genet. 2015;60:749–754.